While semaglutide can be a valuable tool in your weight loss arsenal, it is most effective when combined with lifestyle modifications that promote overall health and well-being
Also, a peer-reviewed study published by earlier this year by the research journal Obesity indicates that only 40% of obese patients taking semaglutide-based GLP-1 products were persistent at one year
In Phase 3 studies: Participants without diabetes taking orforglipron lost approximately 9% to 10% of body weight over roughly 36 to 40 weeks Participants with type 2 diabetes generally lost around 7% to 8% By comparison, Wegovy's landmark STEP trials reported approximately 14.9% average weight loss over 68 weeks
If youre injecting a tirzepatide pen, skip ahead to step 6 after youve performed this step
A treatment for pre-diabetes
Across studies with sufficient initial weight loss for meaningful interpretation, defined here as over 3 kg, the weight regained at or around 12 weeks post-cessation ranged from approximately 10 to 80% of the treatment-induced weight loss